Loading...
Loading...
NUVB| Name | Value |
|---|---|
| Revenues | 1.4M |
| Cost of Revenue | 1.6M |
| Gross Profit | -0.2M |
| Operating Expense | 45.2M |
| Operating I/L | -45.3M |
| Other Income/Expense | 7.9M |
| Interest Income | 7.1M |
| Pretax | -462.5M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -462.5M |
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapeutic candidates for oncology. The company's lead product candidate, NUV-422, is a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. Additionally, it is developing NUV-868, a selective oral small molecule BET inhibitor, NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair, NUV-1182, an adenosine receptor inhibitor, and a drug-drug conjugate (DDC) platform. The company's revenue is generated through the development and potential commercialization of these therapeutic candidates for the treatment of cancer.
